GlassScriptPhysician profile
Rolando Gonzalez
NPI 1205872314
$1,411.16
in general payments reported to CMS, 2019-2025
23 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $133 · 2021: $136 · 2022: $222 · 2023: $159 · 2024: $207 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.76 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.72 | 2019-2025 | |
| Allergan, INC. | $107.38 | 2019-2020 | |
| Hologic Sales and Service, LLC | $86.95 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $83.94 | 2022-2024 | |
| Davol INC. | $60.63 | 2019 | |
| Mayne Pharma Commercial LLC | $58.55 | 2022-2025 | |
| Evofem Biosciences, INC. | $54.83 | 2024-2025 | Solosec, Phexx, Phexxi |
| Mission Pharmacal Company | $54.03 | 2019 | |
| Coopersurgical, INC. | $50.95 | 2024 | Paragard T 380a |
| Astellas Pharma US INC | $48.06 | 2023-2024 | Veozah |
| Duchesnay USA Incorporated | $35.56 | 2019 | |
| Shield Therapeutics INC | $35.10 | 2022-2023 | Accrufer |
| Lupin INC. | $33.66 | 2020 | |
| Lilly USA, LLC | $33.65 | 2021 | |
| Tris Pharma INC | $33.26 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $30.18 | 2019-2021 | |
| Smith+Nephew, INC. | $24.61 | 2024 | Renasys Touch, Pico 14 |
| Exeltis, USA INC. | $22.07 | 2025 | Slynd |
| Alnylam Pharmaceuticals INC. | $20.71 | 2023 | Amvuttra |
| Daiichi Sankyo INC. | $19.69 | 2021 | |
| Ethicon US, LLC | $17.52 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.